ZP1848-17111, A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Glepaglutide in Patients with Short Bowel Syndrome (SBS)

Project: Research project

Project Details

StatusFinished
Effective start/end date9/26/19 → 9/29/22

Funding

  • Pharm-Olam International Ltd. (ZP1848-17111 EASE SBS 1 // ZP1848-17111 EASE SBS 1)
  • Zealand Pharma A/S (ZP1848-17111 EASE SBS 1 // ZP1848-17111 EASE SBS 1)